Abstract
India was one of the most vulnerable countries to the COVID-19 pandemic considering the high transmissibility of the virus, exploding population, and fragile healthcare infrastructure. As an early counter, India implemented a country-wide lockdown and we aimed to study the impact of 4 lockdowns and 2 unlock phases on 6 outcomes: case growth, death count, effective reproduction number, mobility, hospitalization, and infection growth by two methods: interrupted time series (ITR) analysis and Bayesian causal impact analysis (BCIA) for nationals and sub-national levels. We observed that the effects are heterogeneous across outcomes and phases. For example, ITR revealed the effect to be significant for all the outcomes across all phases except for case growth in phase 1. BCIA revealed that the causal effect of all four lockdown phases was positive for deaths. At the state level, Maharashtra benefited from the lockdown in comparison to Tripura. Effects of lockdown phases 3 and 4 on death count were correlated (R=0.70, p<0.05) depicting the ‘extended impact’ of phase-wise interventions. We observed the highest impact on mobility followed by hospitalization, infection growth, effective reproduction number, case growth, and death count. For optimal impact, lockdown needs to be implemented at the sub-national level considering various demographic variations between states.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: None
Competing interests: None declared
Data Availability
All data produced are available online at https://github.com/asarforindia/India-lockdown-impact
